Articles dans des revues avec comité de lecture (36)
  1. 1. Krayem, M., Najem, A., Journé, F., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2024). Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 15, 354. doi:10.18632/oncotarget.28580
  2. 2. Otmani, K., Rouas, R., Lagneaux, L., Krayem, M., Duvillier, H., Berehab, M., & Lewalle, P. (2023). Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways. Cell Communication and Signaling, 21(1), 253. doi:10.1186/s12964-025-02574-5
  3. 3. Otmani, K., Rouas, R., Lagneaux, L., Krayem, M., Duvillier, H., Berehab, M., & Lewalle, P. (2023). Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways. Cell Communication and Signaling, 21(1), 253. doi:10.1186/s12964-023-01259-1
  4. 4. Najem, A., Krayem, M., Sabbah, S., Pesetti, M., Journe, F., Awada, A., Désaubry, L., & Ghanem, G. E. (2023). Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies. Cells, 12(14). doi:10.3390/cells12141855
  5. 5. Sabbah, M., Najem, A., Vanderkerkhove, C., Kert, F., Jourani, Y., Journe, F., Awada, A., Van Gestel, D., Ghanem, G. E., & Krayem, M. (2023). The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma. Frontiers in medicine, 10. doi:10.3389/fmed.2023.1149918
  6. 6. Iliadi Anagnostaki, C., Verset, L., Bouchart, C., Martinive, P., Van Gestel, D., & Krayem, M. (2023). The current understanding of the immune landscape relative to radiotherapy across tumor types. Frontiers in Immunology, 14. doi:10.3389/fimmu.2023.1148692
  7. 7. Kehagias, P., Kindt, N., Krayem, M., Najem, A., Agostini, G., Acedo Reina, E., Bregni, G., Sclafani, F., Journé, F., Awada, A., Ghanem, G. E., & Hendlisz, A. (2022). Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. Cells, 11(22), 3663. doi:10.3390/cells11223663
  8. 8. Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11(7), 1157. doi:10.3390/cells11071157
  9. 9. Alghamdi, H., Dhont, J., Krayem, M., De Bruyn, P., Engels, B., Van Gestel, D., & Van Den Begin, R. (2022). The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers (Basel), 14(8). doi:10.3390/cancers14082046
  10. 10. Krayem, M., Ghanem, G. E., & Van Gestel, D. (2022). Recent advances in radiosensitivity determinants in melanoma. Current opinion in oncology, 34(2), 131-138. doi:10.1097/CCO.0000000000000818
  11. 11. Ajouaou, Y., Azouz, A., Taquin, A., Denanglaire, S., Hind, H. H., Krayem, M., Andris, F., Moser, M., Goriely, S., & Leo, O. (2022). The oxygen sensor Prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells. eLife, 11. doi:10.7554/eLife.70555
  12. 12. De Bakker, T., Journé, F., Descamps, G., Saussez, S., Dragan, T., Atassi, G., Krayem, M., & Van Gestel, D. (2022). Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. Frontiers in oncology, 11. doi:10.3389/fonc.2021.799993
    13. << Précédent 1 2 3 4 Suivant >>